Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Florida Atlantic University Bayer |
---|---|
Information provided by: | Florida Atlantic University |
ClinicalTrials.gov Identifier: | NCT00272311 |
The purpose of the study is to test higher versus lower doses of aspirin on markers of atherosclerosis in patients at risk of a first heart attack.
Condition | Intervention | Phase |
---|---|---|
Cardiovascular Diseases Metabolic Syndrome X Atherosclerosis |
Drug: Aspirin |
Phase IV |
Study Type: | Interventional |
Study Design: | Prevention, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Randomized, Double-Blind Trial to Test Higher- Versus Lower-Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation in High Risk Primary Prevention (Patients With Metabolic Syndrome) |
Estimated Enrollment: | 100 |
Study Start Date: | October 2006 |
Estimated Study Completion Date: | June 2008 |
Arms | Assigned Interventions |
---|---|
1: Active Comparator
81 mg ASA
|
Drug: Aspirin
Dosage
|
2: Active Comparator
162 mg ASA
|
Drug: Aspirin
Dosage
|
3: Active Comparator
325 mg ASA
|
Drug: Aspirin
Dosage
|
4: Active Comparator
650 mg ASA
|
Drug: Aspirin
Dosage
|
5: Active Comparator
1300 mg ASA
|
Drug: Aspirin
Dosage
|
Aspirin reduces risks of heart attacks, strokes, and deaths from cardiovascular causes in patients who have survived a prior event as well as during an acute heart attack. Aspirin also prevents a first heart attack.
Low dose aspirin is sufficient to achieve complete inhibition of platelet aggregability, or stickiness, and this is the mechanism whereby aspirin prevents formation of blood clots.
Our research is designed to explore whether higher doses of aspirin provide additional benefits on markers of atherosclerosis.
Ages Eligible for Study: | 40 Years to 80 Years |
Genders Eligible for Study: | Both |
Inclusion Criteria:
1. Age 40 to 80 years, inclusive.
2. No previous heart attack or a stroke, or other forms of these diseases.
3. Have at least three of the five characteristics listed below, indicating presence of metabolic syndrome, as defined by NCEP-III:
Exclusion Criteria:
United States, Maryland | |
HeartDrug Research, LLC | |
Towson, Maryland, United States, 21204 |
Principal Investigator: | Charles H Hennekens, MD, DrPH | Florida Atlantic University |
Study Director: | Wendy R Schneider, MSN, CCRC | Florida Atlantic University |
Study ID Numbers: | H07-28 |
Study First Received: | January 3, 2006 |
Last Updated: | October 25, 2007 |
ClinicalTrials.gov Identifier: | NCT00272311 |
Health Authority: | United States: Institutional Review Board |
Primary prevention Cardiovascular diseases Aspirin Metabolic Syndrome X Atherosclerosis |
Atherosclerosis Arterial Occlusive Diseases Metabolic Syndrome X Metabolic Diseases Vascular Diseases Arteriosclerosis Nitric Oxide |
Hyperinsulinism Aspirin Syndrome X Insulin Resistance Glucose Metabolism Disorders Metabolic disorder Abdominal obesity metabolic syndrome |
Anti-Inflammatory Agents Disease Molecular Mechanisms of Pharmacological Action Cyclooxygenase Inhibitors Hematologic Agents Physiological Effects of Drugs Enzyme Inhibitors Fibrinolytic Agents Cardiovascular Agents Pharmacologic Actions Fibrin Modulating Agents Pathologic Processes |
Analgesics, Non-Narcotic Sensory System Agents Syndrome Therapeutic Uses Platelet Aggregation Inhibitors Cardiovascular Diseases Anti-Inflammatory Agents, Non-Steroidal Analgesics Peripheral Nervous System Agents Antirheumatic Agents Central Nervous System Agents |